Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XH-S004 Phase I Safety, PK, and Food Effect in Healthy Volunteers
NCT06236841Phase 1Not yet recruiting
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Non-Cystic Fibrosis Bronchiectasis (NCFB) and chronic obstructive pulmonary disease (COPD) comparing XH-S004 with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events (AEs), serious AEs and abnormalities on laboratory tests. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
XH-S004
03
Conditions
Non-Cystic Fibrosis Bronchiectasis (NCFB)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06236841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06236841.